SS-31: Mitochondria-Targeted Peptide Research Overview

SS-31 (also referenced in the literature by its generic name elamipretide) is a synthetic tetrapeptide belonging to the Szeto-Schiller (SS) peptide class, characterized by alternating cationic and aromatic side chains. This structure allows SS-31 to cross the plasma membrane in an energy-independent manner and concentrate strongly — 1,000 to 5,000-fold — at the mitochondrial inner membrane, making it a precision research tool for studying mitochondrial biology.

Note: Elamipretide has received FDA approval for a specific rare pediatric disease indication. Queen BioLabs supplies this compound strictly for laboratory and analytical research purposes; it is not sold, marketed, or intended for human or veterinary use, consumption, or administration in any form.

Foundational research established that SS-31 protects cells against induced oxidative stress by curtailing oxidative cell death, reducing intracellular ROS, and maintaining mitochondrial membrane potential in a dose-dependent manner. Subsequent research across multiple independent research groups has documented efficacy in restoring mitochondrial function across a wide range of preclinical disease models, with research consistently underscoring the compound's favorable safety and pharmacokinetic profile.

Clinical trial research (conducted by Stealth BioTherapeutics under the elamipretide name) has progressed through Phase II and III trials for conditions including Barth syndrome and primary mitochondrial myopathy, resulting in FDA Rare Pediatric Disease designation and, as of September 2025, FDA approval for the Barth syndrome indication — the first-ever approval of a mitochondria-targeted peptide. Separate mechanistic research has examined SS-31's binding to lipid bilayers and its modulation of surface electrostatics as a component of its broader mechanism of action, an area the research community has noted remains incompletely understood despite the compound's substantial clinical validation.